KRAS Activating Mutation clinical trials at University of California Health
2 in progress, 0 open to eligible people
Showing trials for
Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients
Sorry, in progress, not accepting new patients
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with adagrasib in patients with G12C Non-Small Cell Lung Cancer (NSCLC) who have been exposed to prior G12C inhibitor and experienced progressive disease.
at UCSF
Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
Sorry, in progress, not accepting new patients
This study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have been previously untreated.
at UCSF
Our lead scientists for KRAS Activating Mutation research studies include Andrew Ko.
Last updated: